Literature DB >> 25484041

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Kathy Zhang1, Melissa L Geddie, Neeraj Kohli, Tad Kornaga, Dmitri B Kirpotin, Yang Jiao, Rachel Rennard, Daryl C Drummond, Ulrik B Nielsen, Lihui Xu, Alexey A Lugovskoy.   

Abstract

Antibody-targeted nanoparticles have the potential to significantly increase the therapeutic index of cytotoxic anti-cancer therapies by directing them to tumor cells. Using antibodies or their fragments requires careful engineering because multiple parameters, including affinity, internalization rate and stability, all need to be optimized. Here, we present a case study of the iterative engineering of a single chain variable fragment (scFv) for use as a targeting arm of a liposomal cytotoxic nanoparticle. We describe the effect of the orientation of variable domains, the length and composition of the interdomain protein linker that connects VH and VL, and stabilizing mutations in both the framework and complementarity-determining regions (CDRs) on the molecular properties of the scFv. We show that variable domain orientation can alter cross-reactivity to murine antigen while maintaining affinity to the human antigen. We demonstrate that tyrosine residues in the CDRs make diverse contributions to the binding affinity and biophysical properties, and that replacement of non-essential tyrosines can improve the stability and bioactivity of the scFv. Our studies demonstrate that a comprehensive engineering strategy may be required to identify a scFv with optimal characteristics for nanoparticle targeting.

Entities:  

Keywords:  CDR, complementarity-determining region; CLIA, chelated ligand-induced internalization assay; DSF, differential scanning fluorimetry; EphA2, ephrin type-A receptor 2; FACS, fluorescence-activated cell sorting; HTP, high throughput; antibody fragment; antibody-drug conjugate; liposome; manufacturability; nanoparticle; scFv, single chain variable fragment; stability; yeast display

Mesh:

Substances:

Year:  2015        PMID: 25484041      PMCID: PMC4622481          DOI: 10.4161/19420862.2014.985933

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  47 in total

Review 1.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Authors:  Daryl C Drummond; Charles O Noble; Mark E Hayes; John W Park; Dmitri B Kirpotin
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

2.  SCWRL and MolIDE: computer programs for side-chain conformation prediction and homology modeling.

Authors:  Qiang Wang; Adrian A Canutescu; Roland L Dunbrack
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

3.  Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold.

Authors:  Joseph M Perchiacca; Christine C Lee; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2014-01-06       Impact factor: 1.650

Review 4.  Liposomal drug delivery systems: from concept to clinical applications.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

5.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors:  William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2005-09-19       Impact factor: 44.544

6.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Authors:  Ian E Krop; Sung-Bae Kim; Antonio González-Martín; Patricia M LoRusso; Jean-Marc Ferrero; Melanie Smitt; Ron Yu; Abraham C F Leung; Hans Wildiers
Journal:  Lancet Oncol       Date:  2014-05-02       Impact factor: 41.316

7.  High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering.

Authors:  Jason J Lavinder; Sanjay B Hari; Brandon J Sullivan; Thomas J Magliery
Journal:  J Am Chem Soc       Date:  2009-03-25       Impact factor: 15.419

Review 8.  Innate cells and T helper 2 cell immunity in airway inflammation.

Authors:  Nora A Barrett; K Frank Austen
Journal:  Immunity       Date:  2009-09-18       Impact factor: 31.745

9.  The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies.

Authors:  Sara Birtalan; Yingnan Zhang; Frederic A Fellouse; Lihua Shao; Gabriele Schaefer; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2008-02-12       Impact factor: 5.469

10.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

View more
  10 in total

1.  A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).

Authors:  Chao Tu; Virginie Terraube; Amy Sze Pui Tam; Wayne Stochaj; Brian J Fennell; Laura Lin; Mark Stahl; Edward R LaVallie; Will Somers; William J J Finlay; Lydia Mosyak; Joel Bard; Orla Cunningham
Journal:  J Biol Chem       Date:  2015-10-29       Impact factor: 5.157

2.  A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets.

Authors:  John J Rhoden; Gregory L Dyas; Victor J Wroblewski
Journal:  J Biol Chem       Date:  2016-03-28       Impact factor: 5.157

Review 3.  Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications.

Authors:  Robert M Hughes; Jitka A I Virag
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-01

4.  Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences.

Authors:  Thomas Cnudde; Zineb Lakhrif; Justine Bourgoin; Fanny Boursin; Catherine Horiot; Corinne Henriquet; Anne di Tommaso; Matthieu Olivier Juste; Isabella Gizzi Jiacomini; Isabelle Dimier-Poisson; Martine Pugnière; Marie-Nöelle Mévélec; Nicolas Aubrey
Journal:  Antibodies (Basel)       Date:  2020-04-15

5.  Functionalized erythrocyte-derived optical nanoparticles to target ephrin-B2 ligands.

Authors:  Taylor Hanley; Rong Yin; Jenny Mac; Wenbin Tan; Bahman Anvari
Journal:  J Biomed Opt       Date:  2019-08       Impact factor: 3.170

6.  Shelf-Life Extension of Fc-Fused Single Chain Fragment Variable Antibodies by Lyophilization.

Authors:  Kai-Thomas Schneider; Toni Kirmann; Esther Veronika Wenzel; Jan-Hendrik Grosch; Saskia Polten; Doris Meier; Marlies Becker; Paul Matejtschuk; Michael Hust; Giulio Russo; Stefan Dübel
Journal:  Front Cell Infect Microbiol       Date:  2021-11-15       Impact factor: 5.293

7.  CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.

Authors:  Xiuli Wang; Zhenyuan Dong; Dennis Awuah; Wen-Chung Chang; Wesley A Cheng; Vibhuti Vyas; Soung-Chul Cha; Aaron J Anderson; Tiantian Zhang; Zhe Wang; Szymon J Szymura; Benjamin Z Kuang; Mary C Clark; Ibrahim Aldoss; Stephen J Forman; Larry W Kwak; Hong Qin
Journal:  Leukemia       Date:  2022-01-18       Impact factor: 12.883

8.  Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv.

Authors:  Merve Arslan; Murat Karadag; Ebru Onal; Emine Gelinci; Gulcin Cakan-Akdogan; Sibel Kalyoncu
Journal:  Sci Rep       Date:  2022-03-31       Impact factor: 4.379

Review 9.  Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.

Authors:  Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

10.  Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly.

Authors:  Stijn De Munter; Alexander Van Parys; Layla Bral; Joline Ingels; Glenn Goetgeluk; Sarah Bonte; Melissa Pille; Lore Billiet; Karin Weening; Annick Verhee; Jose Van der Heyden; Tom Taghon; Georges Leclercq; Tessa Kerre; Jan Tavernier; Bart Vandekerckhove
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.